Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity
12-week Phase 2a and Phase 1b multiple ascending dose topline results expected to be announced in latter half of fourth quarter 2023 Ethnobridging study initiated in Japanese individuals and... | June 11, 2023